Professor, Medicine, University of Alabama School of Medicine
Rheumatology
Dr. Kenneth G. Saag, MD
|
|
Give Review
Kenneth Saag practices Rheumatology. He attended Northwestern University Feinberg School of Medicine. Northwestern University Feinberg School of Medicine is ranked 19/29 in Research/PrimaryCare. He received awards:"Member", "Meaningful Use Stage 1 Certification", "Fellow (FACP)", "Fellow (FACR)" and "Fellow". Doctor Kenneth G. Saag, MD is a published doctor and has 98 publications published. The lastest was: 'Risk of Herpes Zoster in Auto-immune and Inflammatory diseases: Implications for Vaccination.' He is registered with Medicare.
Publications
- 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.
- Risk of Hospitalized Infection among Biologic-Treated Rheumatoid Arthritis Patients Concurrently Treated with Denosumab.
- Modifiable Factors Associated with Allopurinol Adherence and Outcomes Among Patients with Gout in An Integrated Healthcare System.
- Impact of biologics with and without concomitant MTX and at reduced doses in older rheumatoid Arthritis patients.
- Fracture mortality: associations with epidemiology and Osteoporosis treatment.
- Bisphosphonates and hip and nontraumatic subTrochanteric femoral fractures in the veterans health administration.
- Screening Questions for Nonsteroidal Anti-inflammatory Drug Risk Knowledge.
- Risks of Herpes Zoster in Patients with Rheumatoid Arthritis According to Biologic Disease Modifying Therapy.
- International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study.
- Effect of Self-referral on Bone Mineral Density Testing and Osteoporosis Treatment.
- Use of Oral and Subcutaneous Methotrexate in Rheumatoid Arthritis Patients in the United States.
- A group-randomized trial of shared decision making for non-steroidal anti-inflammatory drug risk awareness: primary results and lessons learned.
- Bone safety of low-dose glucocorticoids in rheumatic Diseases.
- The Recent Prevalence of Osteoporosis and Low Bone Mass in the United States Based on Bone Mineral Density at the Femoral Neck or Lumbar Spine.
- Trends in the utilization and outcomes of medicare patients hospitalized for hip fracture, 2000-2008.
- Risk of hospitalised infection in rheumatoid Arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.
- The clinical diagnosis of Osteoporosis: a position statement from the National Bone Health Alliance Working Group.
- Risk of hospitalized bacterial infections associated with biologic treatment among U.S. Veterans with Rheumatoid Arthritis.
- Empirically Based Composite Fracture Prediction Model from the Global Longitudinal Study of Osteoporosis in Postmenopausal Women (GLOW).
- OMERACT Endorsement of Measures of Outcome for Studies of Acute Gout.
- Glucocorticoid-related bone changes from endogenous or exogenous glucocorticoids.
- Use of health plan combined with registry data to predict clinical trial recruitment.
- Osteopenia: debates and dilemmas.
- Prevention and treatment of bone changes associated with exposure to glucocorticoids.
- Seizure occurrence following nonoptimal anticonvulsant medication management during the transition into the hospital.
- Multimodal intervention to improve Osteoporosis care in home health settings: results from a cluster randomized trial.
- Use of pharmacologic agents for the primary prevention of Osteoporosis among older women with low bone mass.
- TNFs, TB, testing, and treatment: Teeing up the questions.
- Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) Study.
- Death, Debility, and Destitution Following Hip Fracture.
- Trends in the Use of Biologic Therapies among Rheumatoid Arthritis Patients Enrolled in the U.S. Medicare Program.
- Study design considerations for a large simple trial of bisphosphonates.
- Gout-Related Health Care Utilization in US Emergency Departments, 2006 Through 2008.
- Osteoporosis diagnosis and medical treatment.
- Choosing wisely: The American College of Rheumatology's top 5 list of things physicians and patients should question.
- Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.
- Incidence of selected opportunistic infections among children with juvenile idiopathic Arthritis.
- Anticonvulsant medication errors in children with epilepsy during the home-to-hospital transition.
- Physicians' explanations for apparent gaps in the quality of rheumatology care: Results from the US Medicare Physician Quality Reporting System.
- Tumor necrosis factor ? inhibitor therapy and cancer risk in chronic immune-mediated Diseases.
- Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study.
- Association between anti-TNF-? therapy and interstitial lung Disease.
- Short-term and long-term safety of glucocorticoids in rheumatoid Arthritis.
- Generic alendronate use among medicare beneficiaries: are part d data complete?
- A close examination of health care expenditures related to fractures.
- Rilonacept (interleukin-1 trap) for prevention of Gout flares during initiation of uric acid-lowering therapy: Results from a phase III randomized, double-blind, place...
- Serum urate association with hypertension in young adults: analysis from the Coronary Artery Risk Development in Young Adults cohort.
- Rates of hospitalized bacterial infection associated with juvenile idiopathic Arthritis and its treatment.
- A randomized trial of a mailed intervention and self-scheduling to improve Osteoporosis screening in postmenopausal women.
- Physician explanation forapparent gaps in the quality of rheumatology care: Results from the U.S. medicare physician quality reporting system.
- Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United States.
- Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated Diseases.
- Response to a letter from Boers et al.
- Does medication adherence itself confer fracture protection? an investigation of the healthy adherer effect in observational data.
- Recent trends in hip fracture rates by race/ethnicity among older US adults.
- 2012 update of the 2008 american college of rheumatology recommendations for the use of Disease-modifying antirheumatic drugs and biologic agents in the treatment of r...
- Rates of malignancy associated with juvenile idiopathic Arthritis and its treatment.
- Incidence and risk factors for Progressive Multifocal Leukoencephalopathy among patients with selected rheumatic Diseases.
- From Fracture Risk Prediction to Evaluating Fracture Patterns: Recent Advances in the Epidemiology of Osteoporosis.
- Association between being African-American, serum urate levels, and the risk of developing hyperuricemia: findings from the coronary artery risk development in young a...
- Drug Treatment of Hyperuricemia to Prevent Cardiovascular Outcomes: Are We There Yet?
- Central DXA utilization shifts from office-based to hospital-based settings among medicare beneficiaries in the wake of reimbursement changes.
- Mortality due to coronary heart Disease and kidney Disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study.
- Previous fractures at multiple sites increase the risk for subsequent fractures: The global longitudinal study of Osteoporosis in women.
- Developing a provisional definition of flare in patients with established Gout.
- Validation of Diagnostic Codes for SubTrochanteric, Diaphyseal, and Atypical Femoral Fractures Using Administrative Claims Data.
- Initiation of Tumor Necrosis Factor-? Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases.
- Improving Osteoporosis care in high-risk home health patients through a high-intensity intervention.
- Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid Arthritis.
- Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems.
- Patterns of Osteoporosis treatment change and treatment discontinuation among commercial and Medicare Advantage Prescription Drug members in a national health plan.
- Predicting fractures in an international cohort using risk factor algorithms, without bone mineral density.
- Long-term Safety Concerns of Antiresorptive Therapy.
- Potential and pitfalls of using large administrative claims data to study the safety of Osteoporosis therapies.
- Is Two Better Than One? Combining Antiresorptive and Anabolic Osteoporosis Medications.
- The comparative risk of serious infections among rheumatoid Arthritis patients starting or switching biological agents.
- Regional differences in treatment for Osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW).
- 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic Arthritis: initiation and safety monitoring of therapeutic agents for th...
- Should bisphosphonates be used for long-term treatment of glucocorticoid-induced Osteoporosis?
- Communicating non-steroidal anti-inflammatory drug risks: Verbal counseling, written medicine information, and patients' risk awareness.
- American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced Osteoporosis.
- Is withholding Osteoporosis medication after fracture sometimes rational? A comparison of the risk for second fracture versus death.
- Health services utilization after fractures: evidence from Medicare.
- Bone formation markers in patients with glucocorticoid-induced Osteoporosis treated with teriparatide or alendronate.
- The role of health literacy and written medicine information in nonsteroidal antiinflammatory drug risk awareness.
- Health care expenditures associated with skeletal fractures among Medicare beneficiaries, 1999-2005.
- Effects of teriparatide versus alendronate for treating glucocorticoid-induced Osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
- Clinical value of monitoring BMD in patients treated with bisphosphonates for Osteoporosis.
- Patient-reported communications with pharmacy staff at community pharmacies: the Alabama NSAID Patient Safety Study, 2005-2007.
- Population-based fracture risk assessment and Osteoporosis treatment disparities by race and gender.
- Prediction of changes in bone mineral density in postmenopausal women treated with once-weekly bisphosphonates.
- Management of Osteoporosis among home health and long-term care patients with a prior fracture.
- Improving the prediction of medication compliance: the example of bisphosphonates for Osteoporosis.
- Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid Arthritis patients.
- Quality health care gaps in Osteoporosis: how can patients, providers, and the health system do a better job?
- Impact of Osteoporosis treatment adherence on fracture rates in North America and Europe.
- Risk of Herpes Zoster in Auto-immune and Inflammatory Diseases: Implications for Vaccination.
Schools
Northwestern University The Feinberg School Of Medicine
Evanston HospMcGaw Med Center
University Ia
Procedures Preformed
- Joint Drainage
- Steroid Injection
Conditions Treated
- Adhesive Capsulitis
- Amyloidosis
- Ankylosing Spondylitis
- Antiphospholipid Syndrome (APS)
- View All
Doctors Specialties
- Rheumatology
Accepted Insurances
- Aetna
- Blue Card PPO
- Dental Blue 100/200/300
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Coventry Health Care
- First Health (Coventry Health Care) PPO
- HealthSmart
- Choice Care PPO
- Mail Handlers Benefit Plan (MHBP)
- Medicare MCR
- MultiPlan PPO
- National Elevator
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- Member
- Meaningful Use Stage 1 Certification
- Fellow (FACP)
- Fellow (FACR)
- Fellow
Education
-
University of Iowa Hospitals and Clinics -
McGaw Medical Center of Northwestern University -
Northwestern University Feinberg School of Medicine
Hospital
-
University of Alabama Hospital -
Birmingham Veterans Affairs Medical Center
Drug Facts
| NPI NUMBER | 1023033917 | |
| NPPES Provider LastName | SAAG | |
| NPPES Provider FirstName | KENNETH | |
| NPPES Provider ZIPCode | 35233 | |
| NPPES Provider State | AL | |
| Specialty Description | Rheumatology | |
| Total Claim Count | 773.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1023033917 |
| Last Name Of The Provider | SAAG |
| First Name Of The Provider | KENNETH |
| View All |
Similar Doctors
|
|
Dr. Mary Altz-Smith, MD |
|
|
Dr. Stanley L. Bridges, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cornelius B. Thomas Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marcin A. Trojanowski, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Iris Y. Navarro-Millan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Graciela S. Alarcon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joel D. Abbott, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles M. King, MD |
|
|
Dr. Jasvinder Singh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Barri J. Fessler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maria I. Danila, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David M. Spalding, MD
This Doctor is OpenDoctor Recommended.
|